Harmony Drug Patent Portfolio
Harmony owns 1 orange book drug protected by 5 US patents Given below is the list of Harmony's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8207197 | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine | 07 Mar, 2030 | Active |
| US8486947 | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands | 26 Sep, 2029 | Active |
| US8354430 | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine | 06 Feb, 2026 | Active |
| US7910605 | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications | 23 Sep, 2022 | Expired |
| US7169928 | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications | 02 Feb, 2020 | Expired |
Latest Legal Activities on Harmony's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Harmony.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 15 Jul, 2024 | US8354430 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 21 Dec, 2023 | US8207197 |
|
Electronic Review
Critical
| 08 Aug, 2023 | US8207197 |
|
Email Notification
Critical
| 08 Aug, 2023 | US8207197 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 08 Aug, 2023 | US8207197 |
|
Expire Patent
Critical
| 24 Apr, 2023 | US7910605 |
|
Maintenance Fee Reminder Mailed
Critical
| 07 Nov, 2022 | US7910605 |
|
Patent Term Extension Certificate
Critical
| 06 Oct, 2022 | US8207197 |
|
Withdrawal of Application for PTE
Critical
| 30 Aug, 2022 | US8486947 |
| Notice of Final Determination -Election Required | 11 Jul, 2022 | US8486947 |
| Notice of Final Determination -Election Required | 08 Jul, 2022 | US8207197 |
| Notice of Final Determination -Election Required | 08 Jul, 2022 | US8486947 |
|
FDA Final Eligibility Letter
Critical
| 17 Feb, 2022 | US8207197 |
|
FDA Final Eligibility Letter
Critical
| 17 Feb, 2022 | US8486947 |
| transaction for FDA Determination of Regulatory Review Period | 10 Jun, 2021 | US8207197 |
Harmony Drug Patents' Oppositions Filed in EPO
Harmony drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 27, 2014, by Sölch, Günter. This opposition was filed on patent number EP06744466A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP06744466A | Feb, 2014 | Sölch, Günter | Patent maintained as amended |
Harmony's Family Patents
Harmony Drug List
Given below is the complete list of Harmony's drugs and the patents protecting them.
1. Wakix
Wakix is protected by 5 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8207197 | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine |
07 Mar, 2030
(5 years from now)
| Active |
| US8486947 | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands |
26 Sep, 2029
(4 years from now)
| Active |
| US8354430 | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine |
06 Feb, 2026
(1 year, 1 month from now)
| Active |
| US7910605 | Non-imidazole alkylamines as histamine H3- receptor ligands and their therapeutic applications |
23 Sep, 2022
(2 years ago)
| Expired |
| US7169928 | Non-imidazole alkylamines as histamine H3-receptor ligands and their therapeutic applications |
02 Feb, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Wakix's drug page